

Alebund Pharmaceuticals Holds Groundbreaking Ceremony for Yangzhou Research and Production Base

Yangzhou, China, Dec. 7, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, held today a groundbreaking ceremony for its research and production plant in Jiangsu province’s Yangzhou city.

The new plant, located in the bio-industrial park of Yangzhou high-tech zone, will significantly enhance the company’s production capacity for medicines related to chronic renal failure and dialysis complications. The first phase of the project, with an investment of about 1 billion yuan, covers 107 mu of land and construction area of 74,000 square meters. The project, which will produce AP-301 and AP-306 for the treatment of hyperphosphatemia, is expected to be fully completed by the end of 2024.



Chronic kidney disease (CKD) has become a prominent public health problem. The prevalence rate of CKD in China is as high as 10.8%, and the incidence and mortality are increasing year by year, underlining huge unmet medical demand in this field. After the dedicated efforts over last three years, Alebund Pharmaceutical has established a rich and diversified product pipeline. The company's most clinically advanced product, which has best-in-class potential in the treatment of hyperphosphatemia, is currently under Phase II clinical trial and is expected to start Phase III registrational study in 2022.



Zhang Baojuan, Yangzhou municipal party secretary, said: “China is vigorously implementing the strategy to promote the healthcare industry, which represents a major development opportunity. The Yangzhou government is also working hard to build an influential and competitive manufacturing production base as well as a technological innovation base in the Yangtze River Delta region. The new research and production plant of Alebund Pharmaceuticals is an important step in the company’s development, and also a new driving force for quality and efficiency among industrial projects in Yangzhou. We look forward to deepening cooperation with Lilly Asia Ventures and Alebund Pharmaceuticals to promote more high-quality projects in Yangzhou. I’d like to extend my best wishes to the construction of Alebund’s new research and production base and hope the project can run at full capacity as soon as possible.”

Zhang Yaowu, member of the Standing Committee of the Yangzhou Municipal Party Committee and party secretary of the Hanjiang District, said: “The Alebund research and

production project that marked groundbreaking today is an important achievement of investment promotion in the Hanjiang district. After completion, it will become an integrated plant with research, API and drug manufacturing. As China's first biopharmaceutical company focusing on the development of novel renal therapies, Alebund Pharmaceuticals has received investment from Lilly Asia Ventures and many other financial institutions, and has advanced technical equipment as well as clinical development capabilities. We believe that the cooperation between Alebund and Hanjiang will enter a new stage, and Alebund's development will definitely accelerate and become more prosperous. The relevant departments of Yangzhou High-tech Zone will maintain their high efficiency seen previously and continue to provide thoughtful and timely services to ensure that the project will complete construction and enter operation ahead of schedule."



Dr. Chutian Shu, Chief Technology Officer of Alebund and General Manager of Alebund Biopharmaceuticals (Jiangsu) Ltd., said, "The construction of a research and production base in Yangzhou is a major milestone for Alebund to become a fully-fledged biopharmaceutical company with research, clinical development and manufacturing capabilities. Building our own production capacity will bring us advantages in cost and quality control and ensure drug supply, achieve the goal of bringing quality and affordable medicines to patients in need, and accelerate our drive to become a global leader in novel therapies for chronic renal diseases. Due to the large patient

population, numerous complications, and limited treatment options that are safe and effective, there is a significant unmet medical need for novel therapies in chronic renal diseases. We'd like to thank leaders in Yangzhou government for their support and we'll work together to benefit renal patients both in China and globally.”



礼邦医药扬州研发生产基地正式奠基，加速产业化布局

(中国扬州，2021年12月7日) 礼邦医药，一家致力于肾脏病以及相关慢性病药物研发的生物制药公司，今日宣布扬州肾脏疾病领域新药研发生产基地项目正式奠基。新建基地将显著提升公司在慢性肾衰和透析并发症相关药物的产业化生产能力。

新建研发生产基地位于扬州高新区生物健康产业园内，一期项目投资约10亿元，一次性征地约107亩，建筑面积达74000平方米，用于生产高磷血症药品AP-301和AP-306，预计于2024年底前全面建成投产。

慢性肾脏病已成为突出的公共健康问题，而中国慢性肾脏病患病率高达10.8%，且患病率与病死率逐年升高，显示着该领域极大的未被满足的患者需求。经过三年的快速发展，礼邦医药已经建立起了丰富的产品管线，研发进度最快的治疗高磷血症的产品AP-301目前正在临床二期试验，该产品具备全球同类最佳潜力，计划于2022年启动三期注册性临床研究。

扬州市委书记张宝娟表示：“当前国家正大力实施健康中国战略，生物健康产业迎来了重大的发展机遇。我们扬州也在着力打造长三角有影响力竞争力的先进制造业生产基地、产业科技创新高地。此次奠基的礼邦医药肾脏病领域新药研发生产基地，是礼邦医药产业布局的重要一环，必将成为扬州高新区高质量高发展的新支撑和扬州生物健康产业壮大规模、提质增效的新动力。我们期盼能继续与礼来亚洲基金、礼邦医药深化合作，推动更多的优质项目来扬投资发展。祝礼邦医药新药研发生产基地项目建设一帆风顺，早日达产达效。祝礼邦医药未来宏图大展，蒸蒸日上！”

扬州市委常委、政法委书记、邗江区委书记张耀武表示：“今天奠基的礼邦肾脏病新药研发基地项目是邗江招商引资、产业招商、基金招商的重要成果，建成后将成为集研发中试、原料药生产、制剂于一体的产业化基地。礼邦医药作为国内首家肾脏病药物研发企业，得到了礼来亚洲基金和众多金融资本的入股支持，拥有领先的技术装备和临床开发能力。我们相信随着双方合作进入新的阶段，礼邦医药的发展肯定会全面提速，更加兴旺。”

扬州高新区各相关部门要保持前期的高效率，快节奏，继续提供周到、及时的服务，确保项目早建成、早投产、早达效。”

礼邦医药首席技术官兼礼邦生物医药（江苏）有限公司总经理舒楚天博士表示：“新建扬州研发生产基地是礼邦医药加速产业化布局的一项重大举措，建设自主生产能力将为我们创造成本和质量上的优势并且可以有效保证药品供应，实现为患者提供优质且可负担药物的目标，助力于我们成为慢性肾病领域创新药的领军人。肾病患者基数大、并发症多且目前安全有效的药物不多，存在巨大的未被满足临床需求。在此我们感谢扬州各级领导的大力支持，让我们携手共同造福国内及全球慢性肾病患者。”

关于礼邦医药

礼邦医药是一家处于临床阶段的生物制药公司，具有强大的新药研发和临床开发能力。公司主要致力于肾脏病以及其他相关慢性疾病的创新药物发现和开发，为肾脏病及相关慢性疾病患者提供最佳的临床解决方案。礼邦医药已经建立起了丰富且均衡的肾脏病新药产品管线，包括针对慢性肾脏病/透析并发症，IgA 肾病，糖尿病肾病和常染色体显性多囊肾病等产品，公司同时拥有小分子药物和生物制剂在研。